The first-in-class novel prodrug, OBI-3424, has been granted by TFDA to proceed to Phase II clinical trial

1.Date of occurrence of the event:2023/02/16 2.New drug name or code: first-in-class novel prodrug, OBI-3424 3.Indication: OBI-3424 is converted into a potently cytotoxic DNA alkylating agent specifically by the AKR1C3 enzyme, which is expressed by a variety of tumors leading to selective killing of those cells. Potential study subjects will have their tumor cells tested […]